Er-Kim announces exclusive distribution agreement with Puma Biotechnology

Er-Kim announced that it has signed an agreement with Puma Biotechnology (PBYI) to commercialize NERLYNX in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 in order to treat and limit breast cancer metastasis. Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzbekistan. NERLYNX is a prescription medicine used alone to treat adults with early-stage HER2-positive breast cancer and who have previously been treated with trastuzumab-based therapy. NERLYNX is also approved for use with a medicine called capecitabine to treat adults with HER2-positive breast cancer that has spread to other parts of the body and who have received 2 or more anti-HER2 therapy medicines for metastatic breast cancer.